Gender Differences in Progressive Supranuclear Palsy

Gender Differences in Progressive Supranuclear Palsy

Overview

Progressive supranuclear palsy (PSP), also known as [Steele-Richardson-Olszewski syndrome](/diseases/steele-richardson-olszewski-syndrome), is a [4R-tauopathy](/mechanisms/4r-tau-cbs) that exhibits notable differences between male and female patients. Understanding these gender-specific variations is increasingly recognized as important for clinical trial design, treatment decisions, and patient counseling[1]. Gender differences in neurodegenerative diseases extend beyond mere epidemiological observations and may inform our understanding of disease mechanisms, therapeutic responses, and personalized medicine approaches.[@gozes2023]

Epidemiology and Prevalence

Sex Distribution

Epidemiological studies consistently show a male predominance in PSP prevalence.[@mahale2022] A large retrospective analysis of 334 clinically diagnosed PSP patients conducted over 21 years demonstrated a male-to-female ratio of approximately 1.6:1, with 209 male patients (62.2%) and 125 female patients (37.4%)[2]. This male predominance has been reported across multiple cohort studies globally, suggesting a biological basis for the gender disparity rather than simply diagnostic bias.

Gender Differences in Progressive Supranuclear Palsy

Overview

Progressive supranuclear palsy (PSP), also known as [Steele-Richardson-Olszewski syndrome](/diseases/steele-richardson-olszewski-syndrome), is a [4R-tauopathy](/mechanisms/4r-tau-cbs) that exhibits notable differences between male and female patients. Understanding these gender-specific variations is increasingly recognized as important for clinical trial design, treatment decisions, and patient counseling[1]. Gender differences in neurodegenerative diseases extend beyond mere epidemiological observations and may inform our understanding of disease mechanisms, therapeutic responses, and personalized medicine approaches.[@gozes2023]

Epidemiology and Prevalence

Sex Distribution

Epidemiological studies consistently show a male predominance in PSP prevalence.[@mahale2022] A large retrospective analysis of 334 clinically diagnosed PSP patients conducted over 21 years demonstrated a male-to-female ratio of approximately 1.6:1, with 209 male patients (62.2%) and 125 female patients (37.4%)[2]. This male predominance has been reported across multiple cohort studies globally, suggesting a biological basis for the gender disparity rather than simply diagnostic bias.

The male predominance in PSP differs from other neurodegenerative conditions. For example, Alzheimer's disease shows a female predominance, particularly in later age groups, while Parkinson's disease exhibits a slight male excess. The 1.6:1 ratio in PSP places it closer to Parkinson's disease in terms of gender distribution, which may reflect shared underlying mechanisms related to testosterone-mediated neuroprotection or vulnerability.

Incidence Rates

Incidence rates for PSP are estimated at approximately 1-2 per 100,000 person-years in the general population over age 50, with considerable geographic variation. Studies from Europe, North America, and Asia have generally confirmed the male predominance, though the magnitude of the difference varies by population. Some Asian studies have reported a more balanced sex ratio, suggesting potential environmental or genetic modifiers of gender-based risk.

Age at Onset

Research indicates that male PSP patients tend to experience older age at disease onset compared to female patients. Additionally, male patients often present with a [@ye2025]longer duration of illness at the time of initial neurological assessment[2]. This delayed presentation in males may relate to the higher threshold for help-seeking behavior observed in men, or alternatively, could reflect a more insidious disease onset that is recognized later by patients and caregivers.

Female patients, on average, develop PSP approximately 2-3 years earlier than males. This earlier onset in women has implications for disease duration, as women may live with PSP for longer periods, potentially accumulating greater disability before death. The earlier onset in women, combined with faster progression, creates a particularly vulnerable population requiring targeted interventions.

Clinical Phenotype Differences

Motor Symptoms

Despite the epidemiological differences, studies have largely failed to identify significant gender-based differences in motor skills, overall disease severity, or daily living abilities in PSP patients. A large multicenter retrospective analysis of 191 male and 157 female PSP patients in Germany found no significant differences in motor function between genders[1]. However, when examining specific motor features, meaningful differences emerge that may have clinical relevance for diagnosis and management.

Specific motor phenotypes may differ between sexes:

• Tremors are more commonly observed in male PSP patients[2], potentially reflecting differences in basal ganglia circuitry or neurotransmitter systems
• The PSP-parkinsonism (PSP-P) phenotype appears more frequent in males[2], suggesting gender-specific vulnerability to certain tau distribution patterns
• Female patients experience falls within one year of onset more frequently than male patients[2], likely related to the earlier progression of axial symptoms
• Postural instability tends to develop earlier in females, contributing to the earlier fall frequency observed

Apathy: The Male Phenotype

One of the most consistent and clinically significant gender differences identified in PSP is the higher prevalence of apathy among male patients. A 2025 multicenter retrospective study of 348 PSP patients (191 male, 157 female) found that male patients exhibited significantly higher apathy scores compared to female patients[1]. This finding aligns with observations in other neurological diseases where male patients consistently demonstrate higher rates of apathy, including Parkinson's disease, Alzheimer's disease, and traumatic brain injury.

The neurobiological basis for male susceptibility to apathy in PSP likely involves multiple factors:

• Testosterone deficiency has been directly linked to reduced motivation and apathy in various neurological conditions
• Dopaminergic system differences between sexes may affect reward processing and initiative
• Prefrontal cortex involvement in apathy may be more pronounced in males due to sex-specific tau distribution

• Apathy significantly impacts quality of life and functional independence
• Higher apathy in male patients may affect treatment compliance and rehabilitation engagement
• Caregivers of male patients may face unique challenges related to motivational deficits
• This gender difference should be considered in clinical trial outcome measures, as apathy may confound assessment of cognitive and motor function

Cognitive Profile

Gender differences in cognitive presentation have important implications for clinical management and prognosis:

• Female PSP patients demonstrate higher rates of apathy and executive dysfunction compared to males in some studies[2], though this contrasts with the apathy finding in males and may reflect measurement differences
• Female patients show earlier progression to unintelligible speech[2], indicating more rapid brainstem involvement
• Female patients experience earlier onset of severe dysphagia[2], a life-threatening complication requiring early intervention
• Severe cognitive impairment tends to develop earlier in female patients[2], possibly related to faster overall disease progression
• Memory impairment may be more prominent in female PSP patients, suggesting estrogen-related vulnerability to certain cognitive domains

Disease Progression

A critical finding from clinical trials is that female PSP patients experience significantly faster disease progression compared to males. In the davunetide clinical trial, females showed significantly faster deterioration on the PSP Rating Scale (PSPRS) and the Schwab and England Activities of Daily Living (SEADL) scale, with differences becoming apparent as early as trial week 13[3].

Treatment Response Differences

Davunetide: A Sex-Specific Efficacy

One of the most striking examples of gender-based treatment differences in PSP comes from the davunetide clinical trial. This 52-week trial involving over 200 patients revealed dramatic sex-dependent drug efficacy that has reshaped approaches to PSP therapeutic development[3]. The study, initially interpreted as a negative trial when analyzing the total population, became landmark research after post-hoc analysis revealed striking sex-specific effects.

Female-Specific Benefits:

• Significant protection on the SEADL scale at 39 weeks (P = 0.008)[3], demonstrating functional preservation
• Significant protection of bulbar and limb motor domains at 52 weeks, including speaking and swallowing difficulties (P = 0.01)[3], addressing critical quality-of-life domains
• Protection against deterioration of fine motor skills[3], preserving manual dexterity
• Reduced ventricular volume progression[3], suggesting disease-modifying effects on brain atrophy

• Males showed significantly slower disease progression overall compared to females in the placebo arm[3], indicating inherent sex-based differences in disease velocity
• Davunetide did not demonstrate significant efficacy in male patients[3], highlighting the sex-specific nature of the drug's mechanism

• Pooling data irrespective of sex had previously concluded no efficacy for davunetide[3], demonstrating the critical importance of sex-stratified analysis
• Sex-stratified analysis revealed clear efficacy in women[3], transforming a negative trial into a potentially breakthrough therapy
• Future clinical trials should consider sex-stratified randomization and analysis to avoid similar failures to detect real efficacy
• Treatment decisions may eventually be informed by patient sex once biomarkers can predict treatment response

Other Therapeutic Considerations

Beyond davunetide, other therapeutic approaches may demonstrate gender-specific effects in PSP:

• Levodopa responsiveness appears similar between sexes, though some studies suggest females may show better initial response
• Botulinum toxin injections for dystonia show comparable efficacy between genders
• Physical therapy outcomes may differ, with some evidence suggesting women benefit more from intensive rehabilitation programs

Clinical Implications

The gender differences in treatment response highlight the importance of:

• Personalized medicine approaches in PSP based on sex and other biological variables
• Sex-specific analysis in clinical trials as standard practice rather than post-hoc exploration
• Individualized treatment planning based on patient characteristics including gender
• Consideration of sex as a biological variable (SABV) in all research protocols

Neuroimaging Differences

Baseline neuroimaging differences between sexes have been documented in PSP:

• Female PSP patients demonstrate different baseline brain ventricular volumes compared to males[3]
• In placebo-treated females, there is a dramatic correlation between baseline ventricular volume and volume increase at 52 weeks (r = 0.74, P = 2.36-9)[3]
• Davunetide-treated females showed no ventricular volume correlation, similar to males[3]

Caregiver Burden

Impact of Patient Gender

Research on caregiver burden in PSP reveals that the gender of the patient does not significantly affect caregiver burden. Studies found that patient gender (whether male or female) showed no significant effect on caregiver burden (delta r² < 0.01, NS)[4].

Impact of Caregiver Gender

However, caregiver gender does matter:

• Female caregivers report more burden than male caregivers in PSP[4]
• This finding has implications for support services and caregiver interventions

Time Course of Burden

Caregiver burden in PSP follows a predictable pattern:

• Burden increases significantly during the first 18 months post-diagnosis[4]
• After 18 months, burden levels plateau[4]
• The time course of burden mirrors disease severity progression[4]

Hormone Involvement

While direct research on sex hormone involvement in PSP remains limited, evidence from related tauopathies and neurodegenerative diseases provides valuable context for understanding the observed gender differences. Sex hormones exert profound effects on brain development, neuronal survival, and cognitive function, making them plausible modifiers of neurodegeneration in PSP.

Estrogen

Estrogen has demonstrated neuroprotective effects in various neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease. The faster disease progression observed in female PSP patients, particularly post-menopause, suggests potential hormone-related protective mechanisms that warrant investigation[4]. Estrogen exerts multiple protective effects in the brain:

• Anti-inflammatory properties: Estrogen reduces microglial activation and pro-inflammatory cytokine production
• Antioxidant effects: Estrogen directly scavenges free radicals and upregulates endogenous antioxidant enzymes
• Synaptic protection: Estrogen promotes synaptogenesis and dendritic spine formation
• Microtubule stabilization: Estrogen influences tau phosphorylation through kinase and phosphatase pathways

Testosterone

The higher prevalence of apathy in male PSP patients may be related to testosterone levels, as testosterone deficiency has been associated with apathy and reduced motivation in other neurological conditions. Beyond its well-known effects on motivation and reward processing, testosterone influences:

• Cognitive function: Low testosterone correlates with impaired executive function and memory
• Motor control: Testosterone affects basal ganglia function and dopamine signaling
• Neuroprotection: Testosterone has anti-inflammatory and anti-apoptotic properties

Progesterone

Research on related frontotemporal dementias has explored progesterone modulation of [tau pathology](/mechanisms/tau-pathology-pathway) and [TDP-43](/mechanisms/tdp-43-proteinopathy) levels[5], though specific PSP-focused studies are lacking. Progesterone's effects in the brain include:

• Myelin maintenance: Progesterone promotes oligodendrocyte survival and myelination
• Neuroprotection: Progesterone reduces excitotoxicity and promotes neuronal survival
• Tau modulation: In vitro studies suggest progesterone may influence tau phosphorylation states

Melatonin

While not a sex hormone per se, melatonin shows gender-dependent patterns and has been studied in PSP:

• Women generally produce more melatonin than men, and melatonin declines with age in both sexes
• Melatonin has demonstrated neuroprotective effects in tauopathy models
• The interaction between melatonin, sex hormones, and tau pathology in PSP remains unexplored

Clinical Implications of Hormone Research

The emerging understanding of hormone involvement in PSP suggests several clinical considerations:

• Hormone replacement therapy studies in post-menopausal women with PSP may be warranted
• Testosterone supplementation in hypogonadal male PSP patients could potentially improve apathy
• The timing of hormone exposure throughout life may influence PSP risk and progression
• Hormone-based biomarkers may eventually inform prognosis and treatment selection

Research Implications

Clinical Trial Design

The documented gender differences have significant implications for clinical trial design:

• Sex-stratified analysis should be standard in PSP trials
• Endpoint selection may need to account for baseline sex differences
• Sample size calculations should consider sex-specific disease progression rates
• Recruitment strategies should ensure adequate female representation

Future Research Directions

Key areas requiring further investigation include:

• Mechanisms underlying the male apathy phenotype
• Hormone replacement therapy studies in PSP
• Sex-specific biomarker development
• Genetic factors influencing sex differences in PSP

Conclusion

Significant gender differences exist in PSP regarding clinical presentation, disease progression, treatment response, and caregiver impact. Male patients exhibit higher rates of apathy, while female patients demonstrate faster disease progression and specific benefits from certain therapies. These differences underscore the importance of personalized approaches to PSP management and the critical role of sex-specific analysis in both research and clinical practice.

The recognition of gender differences in PSP represents a paradigm shift toward precision medicine in this devastating disease. The dramatic sex-specific effects observed with davunetide demonstrate that treatments may have vastly different efficacy depending on patient sex, and that pooling data across sexes may obscure real therapeutic benefits. As the field moves forward, sex-stratified analysis should become standard in all PSP clinical trials, and clinicians should consider gender as a factor in treatment planning and prognostic counseling.

Future research priorities include: elucidating the biological mechanisms underlying the male apathy phenotype, investigating hormone replacement therapy as a potential disease-modifying strategy, developing sex-specific biomarker panels for diagnosis and prognosis, and identifying genetic factors that may explain the observed gender differences in PSP incidence and progression. The integration of sex-based considerations into PSP research and clinical care represents an important step toward more effective, personalized treatments for this underserved patient population.

See Also

• [Steele-Richardson-Olszewski syndrome](/diseases/steele-richardson-olszewski-syndrome)
• [4R-tauopathy](/mechanisms/4r-tau-cbs)
• [tau pathology](/mechanisms/tau-pathology-pathway)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References